97 related articles for article (PubMed ID: 24304256)
1. Out-of-pocket costs and prescription reversals with oral linezolid.
Pasquale MK; Louder AM; Deminski MC; Chambers RB; Haider S
Am J Manag Care; 2013 Sep; 19(9):734-40. PubMed ID: 24304256
[TBL] [Abstract][Full Text] [Related]
2. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
[TBL] [Abstract][Full Text] [Related]
5. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
6. Comparing the use of intravenous antibiotics under the medical benefit with the use of oral antibiotics under the pharmacy benefit in treating skin and soft tissue infections.
Barron J; Turner R; Jaeger M; Adamson W; Singer J
Manag Care; 2012 Sep; 21(9):44-52. PubMed ID: 23050424
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
[TBL] [Abstract][Full Text] [Related]
8. Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals.
Ball AT; Xu Y; Sanchez RJ; Shelbaya A; Deminski MC; Nau DP
Clin Ther; 2010 Dec; 32(13):2246-55. PubMed ID: 21316540
[TBL] [Abstract][Full Text] [Related]
9. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.
Shorr AF; Susla GM; Kollef MH
Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain.
Grau S; Aguado JM; Mateu-de Antonio J; Gonzalez P; Del Castillo A
J Chemother; 2007 Aug; 19(4):398-409. PubMed ID: 17855184
[TBL] [Abstract][Full Text] [Related]
11. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
[TBL] [Abstract][Full Text] [Related]
12. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
Wilcox M; Nathwani D; Dryden M
J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
[TBL] [Abstract][Full Text] [Related]
14. Linezolid: the first oxazolidinone antimicrobial.
Lindley DA
Ann Intern Med; 2003 Nov; 139(10):863; author reply 864. PubMed ID: 14623625
[No Abstract] [Full Text] [Related]
15. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.
Caffrey AR; Morrill HJ; Puzniak LA; Laplante KL
Pharmacotherapy; 2014 May; 34(5):473-80. PubMed ID: 24420846
[TBL] [Abstract][Full Text] [Related]
16. [Utility of linezolid in cystic fibrosis].
Girón-Moreno RM; Ruiz-Velasco LM; Buendía V
Enferm Infecc Microbiol Clin; 2004; 22(6):369-70. PubMed ID: 15228910
[No Abstract] [Full Text] [Related]
17. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus.
Menzin J; Marton JP; Meyers JL; Carson RT; Rothermel CD; Friedman M
Am J Infect Control; 2010 Feb; 38(1):44-9. PubMed ID: 19762120
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Sharpe JN; Shively EH; Polk HC
Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms.
Grau S; Mateu-de Antonio J; Soto J; Marín-Casino M; Salas E
Pharm World Sci; 2005 Dec; 27(6):459-64. PubMed ID: 16341954
[TBL] [Abstract][Full Text] [Related]
20. Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008.
Walberg MP; Patel RA; Amaral MM
J Med Econ; 2008; 11(4):625-37. PubMed ID: 19450072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
